Pantoprazole 40mg + Domperidone 10mg Tablets are a combination- solid oral formulation designed to contain two active pharmaceutical ingredients at the noted tablet strengths. Pantoprazole is combined at 40mg strength and Domperidone at 10mg per-unit strength. The development of combination tablets requires an approach to formulation development that takes into account the individual properties of each API, stable formulation and dosage uniformity considerations.
For any new company development of combination tablet form for the oral dose form this can be delivered as part of a professional oriented PCD Pharma Franchise product portfolio.
The finished product contains each active pharmaceutical ingredient along with pharmaceutical excipients chosen according to the formulation requirements. Each excipient formulation design can contribute to powder flow, binding, compression, disintegration, coating, and physical form. The formulation can be established by formulation-development studies and production specification requirements.
The manufacturing process begins with API qualification (Pantoprazole + Domperidone APIs) and entry into finished formulation production.
Each raw material is subjected to supplier qualification exercises according to relevant product specifications as laid down by the starting material specifications.
Assessment of API can include identification, assay, related compounds, moisture content, granulation characteristics, flowability, and other suitable testing. Calibrated weighing systems and systematic dispensing processes can help to minimize material variation in combination formulation production. The dispensed formulation is conveyed to the designated production zone under controlled conditions.
Pantoprazole and Domperidone may require very different handling considerations so that their physicochemical properties are not necessarily in agreement. The formulation development project evaluates the particulate material characteristics and thereby chooses an appropriate tabletting method for a uniformly distributed content.
This process is defined during the formulation development project and maintained through the establishment of production specifications. During blend/ granulation the parameters to be controlled and monitored, where applicable, may include mixer charge times, granulation conditions, spray conditions, inert atmosphere, and tablet line speed/ throughput. The finished formulation is checked to meet in-process specification before tabletting operations proceed. Tablet compression is performed in suitable tablet presses under controlled speed and force parameters.
Tablet physical parameters such as weight, thickness, friability, diameter, appearance, and hardness are tested during the tabletting process, and techniques established during formulation development are in place.
Where applicable, during-coating parameters such as spray rate, spray pattern, spray time, and oven temperature are also measured and adjusted to ensure consistent coating quality across several batch runs. If film-coating of tablets occurs, the tablets are coated in a controlled spray enclosure. Coating parameters such as spray rate and pattern, spray time, and oven temperature are all monitored.
A uniform coating uniformity, tablet weight gain, and absence of coating defects or tablet chipping are monitored for each batch run.
Pantoprazole 40mg + Domperidone 10mg tablets testing can include testing of both APIs and the finished formulation according to the specification for each constituent part and the whole. Testing of finished product formulation according to industry-acceptable standards of methodology, which can include as specified identification of each constituent API, assay of each API, related substances, dissolution, disintegration, weight variation and average weight, hardness, friability, and appearance.
Individual specification testing of the Pantoprazole and Domperidone active pharmaceutical agents can be performed in order to establish that the specified dosage strength has been maintained through production.
Uniformity testing of the finished formulation can include a sampling of an adequate number of dosage units (as specified in the test method) and determination of the content of each constituent API in each individual dose. If the 10mg strength is much smaller or larger than the 40mg and to minimize the absolute mass variation, the sampling and analytical procedures may take into account the small dose. The analytical method used can be suitably validated or validated for the product type, and the use of calibrated equipment, reference standards, documented test procedures, and record review can be appropriate to ensure that observed measurements are accurate and repeatable. Batch release specifications can be met or exceeded before release for storage and distribution.
Batch manufacturing records, room clearances, equipment cleaning documentation, in-process results, and finished formulation results are collected for review, testing, and release of each production batch.
A formulation-specific stability testing program can be devised to test the ability of Pantoprazole 40mg + Domperidone 10mg tablets to be maintained at the correctly-determined specification throughout storage. Stability samples of the finished formulation can be stored in conditions of temperature, humidity, and light according to the formulation as well as regulatory requirements, and periodic testing can be conducted to determine the stability of the finished formulation over time. The stability testing may include appearance, assay of each constituent API, related substances, dissolution, physical parameters, and other suitable testing.
Monitoring the stability of each API allows the overall stability of the formulation to be evaluated. The choice of packaging materials is an important element in the formulation to support finished API stability. Depending on the tabletting and stability requirements, the finished formulation may be packaged in a suitable blister strip, strip, or other packaging system, and the materials chosen for packaging may be tested for compatibility and their ability to provide an adequate barrier to light and moisture.
Primary and secondary packaging can be characterized to allow a suitable level of protection during storage and shipment, as well as ensuring correct product identification, batch numbering, and sealing.
Pantoprazole 40mg + Domperidone 10mg tablets are capable of systematic product portfolio management according to formulated approaches to formulation design, manufacturing, quality monitoring, stability testing, and packaging. For organizations working with a PCD Pharma Franchise, consistent finished production specifications for each batch of production can help to establish an organized process of finished product planning and distribution. The formulation development plan may include API sourcing and qualification, excipient qualification, formulation/process development, analytical method validation/verification, stability testing, packaging selection, and batch qualification. Each step can help ensure an organized pathway of product management and distribution.
For portfolio expansion, this product concept can be included alongside other oral pharmaceutical products in a PCD Pharma Franchise product portfolio with the inclusion of professionally established product documentations and packaging systems.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech